SoftOx Solutions AS announced that the New Board and Leadership. The founder and current Chairman of the Board, Geir Almås, has decided to step down. New Board and Management: Ulrik Spork has accepted to take the position of Chairman of the Board in SoftOx Solutions AS.

He has gained massive support from a majority of the shareholders and is in the process of identifying additional qualified candidates with relevant complementing competencies to be proposed as additional members of the board. It has also been agreed that Professor Thomas Bjarnsholt will fill the position as CEO. This will be a very strong and experienced team.

The Board will therefore propose to the EGM to elect Ulrik Spork as the new Chairman of the Board. Ulrik Spork is active as chairman/board member in a number of emerging life-science companies as well as two funds-of-funds, investing in venture/private equity funds. Over 25 years until 2015 Ulrik held senior positions in the Novo Group, including Head of Corporate Development in Novo Nordisk, founder and Senior Partner of Novo Ventures, Managing Partner Novo Growth Equity and Principal Investments and member of the executive team in Novo Holdings A/S. Over the last 25+ years, Ulrik has served as chairman or board member in more than 30 development/early commercialization stage companies in the life science space, in jurisdictions including France, UK, Sweden, Denmark Canada and USA.

This has provided him with relevant experience and network, but he also brings a pragmatic approach and an appreciation of the need for pre-revenue life-science companies to thoughtfully navigate towards value inflection points, to successfully advance. He is a Danish national and holds a master's degree in engineering from Danish Technical University and a bachelor's in business administration from Copenhagen Business School. Thomas Bjarnsholt has been consultant of SoftOx since 2017 and CSO since 2022.

Bjarnsholt has been instrumental and leading the development of the SoftOx technology for inhalation purposes. He is an expert in bacterial biofilms and their role in chronic infections. He has carried out pioneering work by being the first to identify and visualize bacterial biofilms in chronic wounds, acute and chronic lung infections, chronic middle ear infections and infections due to tissue fillers.